Keybank National Association OH lifted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 2.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 70,137 shares of the medical instruments supplier’s stock after buying an additional 1,598 shares during the quarter. Keybank National Association OH’s holdings in Becton Dickinson and were worth $17,742,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently modified their holdings of the company. TRUE Private Wealth Advisors purchased a new position in Becton Dickinson and in the 2nd quarter valued at approximately $25,000. Allworth Financial LP grew its stake in Becton Dickinson and by 386.4% in the 3rd quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 85 shares in the last quarter. Northwest Investment Counselors LLC purchased a new position in Becton Dickinson and in the 3rd quarter valued at approximately $27,000. Hexavest Inc. purchased a new position in Becton Dickinson and in the 2nd quarter valued at approximately $28,000. Finally, Lipe & Dalton purchased a new position in Becton Dickinson and in the 2nd quarter valued at approximately $28,000. Institutional investors own 84.29% of the company’s stock.
In other news, EVP James C. Lim sold 9,299 shares of Becton Dickinson and stock in a transaction on Friday, September 6th. The shares were sold at an average price of $263.53, for a total transaction of $2,450,565.47. Following the completion of the sale, the executive vice president now directly owns 33,041 shares of the company’s stock, valued at approximately $8,707,294.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vincent A. Forlenza sold 11,532 shares of Becton Dickinson and stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the sale, the chief executive officer now directly owns 218,671 shares of the company’s stock, valued at $56,937,554.98. The disclosure for this sale can be found here. Insiders have sold a total of 32,174 shares of company stock valued at $8,354,013 over the last ninety days. 0.12% of the stock is currently owned by insiders.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.30 by $0.01. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.51%. The firm had revenue of $4.58 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same period last year, the firm earned $2.93 EPS. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. Equities research analysts anticipate that Becton Dickinson and Co will post 12.58 earnings per share for the current year.
A number of research analysts recently weighed in on BDX shares. Piper Jaffray Companies reduced their price objective on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. ValuEngine lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Wells Fargo & Co reduced their price objective on shares of Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, Morgan Stanley lifted their price objective on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. Five analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and currently has an average rating of “Buy” and an average price target of $266.09.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: 52-Week High/Low
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.